Rep. Griffith’s Compounding Draft Ties FDA Inspections To State Reporting
This article was originally published in The Pink Sheet Daily
Rep. Griffith circulates a discussion draft with new procedures for states to tell FDA when they have found problems at a compounder, but only then could the agency inspect the facility.
You may also be interested in...
HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.
After House Republicans indicate legislation expanding agency’s oversight of compounding is unlikely, FDA could consider other regulatory options, like changing internal policies or hoping a court clarifies its regulatory authority.
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.